Innate Pharma SA announces the entry in pre-clinical validation of a new drug candidate: IPH 4201.
IPH 4201 is a monoclonal antibody targeting a specific antigen on pancreatic cancer cells.
| PR in english | 40.84 KB |
| CP en français | 41.35 KB |
Innate Pharma SA announces the entry in pre-clinical validation of a new drug candidate: IPH 4201.
IPH 4201 is a monoclonal antibody targeting a specific antigen on pancreatic cancer cells.
| PR in english | 40.84 KB |
| CP en français | 41.35 KB |